| Bridgepoint Subacute And Rehab National Harbor | |
| 4601 Martin Luther King Jr Avenue Sw, Washington, District Of Columbia 20032 | |
| (202) 279-3005 | |
| Name | Bridgepoint Subacute And Rehab National Harbor |
|---|---|
| Location | 4601 Martin Luther King Jr Avenue Sw, Washington, District Of Columbia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 62 |
| Occupancy Rate | 183.06% |
| Medicare ID (CCN) | 095024 |
| Legal Business Name | Dca Hadley Snf, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1356456289 |
| Organization Name | DCA HADLEY SNF LLC |
| Doing Business As | BRIDGEPOINT SUB-ACUTE & REHABILITATION NATIONAL HARBORSIDE |
| Address | 4601 Mlk Jr Avenue Sw, Washington, DC 20032 |
| Phone Number | 202-741-4170 |
News Archive
The most prestigious peer-reviewed journals in the world, such as Cell, Nature, Science, and the Journal of the American Medical Association (JAMA), have less and less influence amongst scientists, according to a paper co-authored by Vincent Larivière, a professor at the University of Montreal's School of Library and Information Sciences.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
One study suggested that 42 percent of people with type 2 diabetes who are treated for the disease do not reach their blood sugar goals, putting them at higher risk of organ and tissue damage, blindness and even death. We wanted to explore potential causes of clinical inertia among physicians and people with diabetes, which may lead to sub-optimal care.
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The most prestigious peer-reviewed journals in the world, such as Cell, Nature, Science, and the Journal of the American Medical Association (JAMA), have less and less influence amongst scientists, according to a paper co-authored by Vincent Larivière, a professor at the University of Montreal's School of Library and Information Sciences.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
One study suggested that 42 percent of people with type 2 diabetes who are treated for the disease do not reach their blood sugar goals, putting them at higher risk of organ and tissue damage, blindness and even death. We wanted to explore potential causes of clinical inertia among physicians and people with diabetes, which may lead to sub-optimal care.
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $13000 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.49 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.44 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.29 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.25 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.06 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.46 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 78.65 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.06 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 17.95 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.28 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 50.56 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.2 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 14.29 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.5 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 69.58 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 50.76 | 82.93 |
News Archive
The most prestigious peer-reviewed journals in the world, such as Cell, Nature, Science, and the Journal of the American Medical Association (JAMA), have less and less influence amongst scientists, according to a paper co-authored by Vincent Larivière, a professor at the University of Montreal's School of Library and Information Sciences.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
One study suggested that 42 percent of people with type 2 diabetes who are treated for the disease do not reach their blood sugar goals, putting them at higher risk of organ and tissue damage, blindness and even death. We wanted to explore potential causes of clinical inertia among physicians and people with diabetes, which may lead to sub-optimal care.
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
› Verified 5 days ago
Washington Ctr For Aging Svcs Location: 2601 18th Street Ne, Washington, District Of Columbia 20018 Phone: (202) 541-6140 | |
Serenity Rehabilitation And Health Center Llc Location: 1380 Southern Ave Se, Washington, District Of Columbia 20032 Phone: (202) 279-5880 | |
Deanwood Rehabilitation And Wellness Center Location: 5000 Burroughs Ave. Ne, Washington, District Of Columbia 20019 Phone: (202) 399-7504 | |
Stoddard Baptist Nursing Home Location: 1818 Newton St. Nw, Washington, District Of Columbia 20010 Phone: (202) 328-7400 | |
Capitol City Rehab And Healthcare Center Location: 2425 25th Street Se, Washington, District Of Columbia 20020 Phone: (202) 889-3600 | |
Bridgepoint Subacute And Rehab National Harbor Location: 4601 Martin Luther King Jr Avenue Sw, Washington, District Of Columbia 20032 Phone: (202) 279-3005 |